Analyst Serge Belanger from Needham maintained a Buy rating on Oculis Holding and keeping the price target at $36.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Serge Belanger’s rating is based on several promising developments within Oculis Holding’s pipeline. The company has three programs in late-stage development, with particular emphasis on the phase 3 trials of OCS-01 in diabetic macular edema (DME), which are anticipated to yield results in the second quarter of 2026. These results are crucial as they are expected to support a New Drug Application (NDA) filing later that year, marking a significant milestone for the company.
Additionally, Oculis Holding’s financial position is robust, with a pro-forma cash reserve of $292 million following a recent equity raise. This financial strength is projected to sustain the company until 2029, providing a solid foundation for its ongoing and future projects. The combination of these factors, including the potential for transformational data from the upcoming trials, underpins Belanger’s Buy rating and the $36 price target for the stock.